MX2022009962A - Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2. - Google Patents
Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2.Info
- Publication number
- MX2022009962A MX2022009962A MX2022009962A MX2022009962A MX2022009962A MX 2022009962 A MX2022009962 A MX 2022009962A MX 2022009962 A MX2022009962 A MX 2022009962A MX 2022009962 A MX2022009962 A MX 2022009962A MX 2022009962 A MX2022009962 A MX 2022009962A
- Authority
- MX
- Mexico
- Prior art keywords
- cov2
- sars
- vaccines
- induce
- immune response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
- C12N15/8636—Vaccina virus vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976913P | 2020-02-14 | 2020-02-14 | |
| US202062977402P | 2020-02-16 | 2020-02-16 | |
| US202062992710P | 2020-03-20 | 2020-03-20 | |
| US202063026580P | 2020-05-18 | 2020-05-18 | |
| PCT/US2021/018033 WO2021163622A1 (en) | 2020-02-14 | 2021-02-12 | Vaccines and uses thereof to induce an immune response to sars-cov2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009962A true MX2022009962A (es) | 2022-11-09 |
Family
ID=77292751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009962A MX2022009962A (es) | 2020-02-14 | 2021-02-12 | Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12577589B2 (https=) |
| EP (1) | EP4103231A4 (https=) |
| JP (1) | JP2023513611A (https=) |
| KR (1) | KR20220154114A (https=) |
| CN (1) | CN115529817A (https=) |
| AU (1) | AU2021220991A1 (https=) |
| BR (1) | BR112022014884A2 (https=) |
| CA (1) | CA3167052A1 (https=) |
| IL (1) | IL295482A (https=) |
| MX (1) | MX2022009962A (https=) |
| TW (1) | TW202140794A (https=) |
| WO (1) | WO2021163622A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3986447A4 (en) * | 2019-06-18 | 2023-08-16 | Citranvi Biosciences, LLC | RATIONALLY MANIPULATED CARRIER PROTEINS FOR VACCINES |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| MX2022010985A (es) * | 2020-03-04 | 2023-04-19 | Premas Biotech Pvt Ltd | Expresión de proteínas sars-cov, constructos de ácido nucleico, proteínas tipo virus (vlp) y métodos relevantes a los mismos. |
| EP4132576A1 (en) * | 2020-04-09 | 2023-02-15 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| EP4164682A1 (en) * | 2020-06-10 | 2023-04-19 | Bavarian Nordic A/S | A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease |
| US20230295655A1 (en) * | 2020-07-31 | 2023-09-21 | Tokyo Metropolitan Institute Of Medical Science | Recombinant vaccinia virus |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| US20230002780A1 (en) * | 2021-06-25 | 2023-01-05 | Applied Biotechnology Institute, Inc. | EXPRESSION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) SPIKE PROTEIN SEQUENCES IN PLANTS AND PLANT PRODUCED VACCINE FOR SAME |
| WO2023020939A1 (en) * | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| KR20230031756A (ko) * | 2021-08-27 | 2023-03-07 | 한국과학기술원 | 신종 코로나바이러스 감염증 대응 예방 백신 조성물 |
| WO2023057979A1 (en) * | 2021-10-07 | 2023-04-13 | Precision NanoSystems ULC | Rna vaccine lipid nanoparticles |
| WO2023069461A2 (en) * | 2021-10-19 | 2023-04-27 | Vaxxinity, Inc. | Method for the prevention and treatment of coronavirus disease |
| WO2023092023A2 (en) * | 2021-11-17 | 2023-05-25 | City Of Hope | Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19) |
| WO2023200858A1 (en) * | 2022-04-13 | 2023-10-19 | The Trustees Of Columbia University In The City Of New York | Inhibitory peptides against coronaviruses |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| GB2624391A (en) * | 2022-11-15 | 2024-05-22 | Univ Cape Town | Recombinant LSDV vectored bovine coronavirus antigen constructs |
| WO2024118079A1 (en) * | 2022-12-01 | 2024-06-06 | Vaxxinity, Inc. | Method for the prevention and treatment of coronavirus disease |
| WO2024206243A1 (en) * | 2023-03-24 | 2024-10-03 | Geovax. Inc. | Pan-betacoronavirus vaccines and uses thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE787901A (fr) | 1971-09-11 | 1972-12-18 | Freistaat Bayern Represente Pa | Vaccin antivariolique |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| DK0538496T3 (da) | 1991-08-26 | 2004-02-23 | Baxter Healthcare Sa | Rekombinant fjerkrækoppevirus med intakt FPV tk-gen |
| WO1994012617A1 (en) | 1992-11-25 | 1994-06-09 | International Biotechnology Laboratories, Inc. | Hepatitis b virus vaccines |
| AU4088697A (en) | 1996-08-26 | 1998-03-19 | Chiron Corporation | Postinfection human immunodeficiency virus (hiv) vaccination therapy |
| AUPP380598A0 (en) | 1998-05-29 | 1998-06-25 | Commonwealth Scientific And Industrial Research Organisation | Genetically manipulated entomopoxvirus |
| US6294176B1 (en) | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
| JP4554887B2 (ja) | 2001-03-08 | 2010-09-29 | アメリカ合衆国 | 改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ |
| WO2003078640A2 (en) | 2002-03-15 | 2003-09-25 | Baxter International Inc. | Recombinant drug-sensitive vaccinia virus as smallpox vaccine |
| ATE315660T1 (de) | 2002-05-16 | 2006-02-15 | Bavarian Nordic As | Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva) |
| US9045727B2 (en) * | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| CA2501168A1 (en) | 2002-11-25 | 2004-06-10 | Bavarian Nordic A/S | Recombinant poxvirus comprising at least two cowpox ati promoters |
| EP2363493B1 (en) | 2003-02-20 | 2012-11-14 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
| US20070092936A1 (en) | 2003-05-08 | 2007-04-26 | Haynes Barton F | Severe acute respiratory syndrome |
| US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
| US8541003B2 (en) | 2003-06-20 | 2013-09-24 | Protein Sciences Corporation | Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using |
| CN1918288A (zh) * | 2003-06-20 | 2007-02-21 | 蛋白质科学公司 | 表达sars免疫原的载体、含所述载体或其表达产物的组合物、制备和使用方法和实验 |
| WO2005047459A2 (en) * | 2003-08-04 | 2005-05-26 | University Of Massachusetts | Sars nucleic acids, proteins, antibodies, and uses thereof |
| WO2006071250A2 (en) | 2004-04-05 | 2006-07-06 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Soluble fragments of the sars-cov spike glycoprotein |
| CA2569142A1 (en) * | 2004-06-02 | 2005-12-22 | New York Blood Center | Sars vaccines and methods to produce highly potent antibodies |
| JPWO2006022215A1 (ja) * | 2004-08-23 | 2008-05-08 | 財団法人ヒューマンサイエンス振興財団 | ＳＡＲＳ−コロナウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用 |
| US9453239B2 (en) | 2004-08-27 | 2016-09-27 | Emory University | Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes |
| CA2587084C (en) * | 2004-10-08 | 2019-07-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by using less frequently used synonym ous codons |
| CN100479858C (zh) * | 2005-01-27 | 2009-04-22 | 中国医学科学院实验动物研究所 | 一种重组痘苗-sars疫苗及其制备方法 |
| ES2281252B1 (es) | 2005-07-27 | 2009-02-16 | Consejo Superior De Investigaciones Cientificas | Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida. |
| DK2062023T4 (en) | 2006-08-25 | 2017-02-20 | The Government Of The Us Secretary Dept Of Health And Human Services | INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS |
| JP5683476B2 (ja) | 2008-11-03 | 2015-03-11 | タケダ ヴァクシーンズ， インコーポレイテッド | 感染因子を含まないエンベロープウイルスベースｖｌｐを単離するための改良法 |
| AP2012006258A0 (en) | 2009-10-13 | 2012-06-30 | Geovax Inc | Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens. |
| DK2488649T3 (da) | 2009-10-16 | 2019-06-17 | Us Health | Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder |
| WO2011103417A2 (en) | 2010-02-18 | 2011-08-25 | Emory University Of Technology Transfer | Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response |
| TWI526539B (zh) * | 2010-12-22 | 2016-03-21 | 苜蓿股份有限公司 | 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp |
| WO2013059498A1 (en) | 2011-10-18 | 2013-04-25 | Geovax, Inc. | Mva vectors expressing polypeptides and having high level production in certain cell lines |
| US20150140068A1 (en) | 2012-07-06 | 2015-05-21 | Novartis Ag | Immunogenic compositions and uses thereof |
| WO2015009946A1 (en) | 2013-07-17 | 2015-01-22 | Emory University | Method of increasing immune response to hiv antigens |
| WO2015066715A1 (en) | 2013-11-04 | 2015-05-07 | Viracell Advanced Products, Llc | Virus-like particles and methods related thereto |
| ES2851451T3 (es) | 2014-05-13 | 2021-09-07 | Bavarian Nordic As | Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3 |
| EP3188752A2 (en) | 2014-09-03 | 2017-07-12 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
| WO2016068919A1 (en) | 2014-10-29 | 2016-05-06 | Geovax, Inc. | Combination therapy for treating viral reservoirs |
| US11701418B2 (en) | 2015-01-12 | 2023-07-18 | Geovax, Inc. | Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) |
| EP3045181B1 (en) | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV) |
| WO2017120577A1 (en) * | 2016-01-08 | 2017-07-13 | Geovax Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
| RS61118B1 (sr) * | 2016-01-12 | 2020-12-31 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Sredstva i postupci za lečenje hbv |
| WO2017136419A1 (en) | 2016-02-03 | 2017-08-10 | Geovax Inc. | Compositions and methods for generating an immune response to a flavivirus |
| EP3416978A4 (en) | 2016-02-16 | 2019-11-06 | Geovax, Inc. | MULTIVALENT HIV VACCINE BOOST COMPOSITION AND METHOD OF USE |
| WO2017210181A1 (en) | 2016-05-30 | 2017-12-07 | Geovax Inc. | Compositions and methods for generating an immune response to hepatitis b virus |
| US10960070B2 (en) | 2016-10-25 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| IL288737B (en) | 2017-02-01 | 2022-09-01 | Atea Pharmaceuticals Inc | Hemisulfate nucleotide salt for treatment of hepatitis c virus |
| EP3595676A4 (en) * | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
| WO2018195447A1 (en) | 2017-04-20 | 2018-10-25 | Geovax Labs, Inc. | Recombinant mva-based hiv immunogens and uses thereof |
| WO2019018501A1 (en) | 2017-07-18 | 2019-01-24 | Geovax Inc. | COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE |
| WO2019040846A1 (en) | 2017-08-25 | 2019-02-28 | Geovax Inc. | IMMUNO-ONCOLOGY COMPOSITIONS AND METHODS OF USE THEREOF |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| WO2020247547A1 (en) | 2019-06-03 | 2020-12-10 | Geovax, Inc. | Cancer vaccine compositions and methods for use thereof |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| CA3168836A1 (en) | 2020-02-03 | 2021-08-12 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
| WO2021163365A1 (en) | 2020-02-11 | 2021-08-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sars-cov-2 vaccine |
| GB2594683A (en) | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
| KR20220165731A (ko) * | 2020-02-26 | 2022-12-15 | 토닉스 파마 리미티드 | Sars-cov-2 바이러스에 대한 재조합 폭스바이러스 기반 백신 |
| JP2023517286A (ja) | 2020-03-13 | 2023-04-25 | オックスフォード ユニヴァーシティ イノヴェーション リミテッド | 免疫応答を誘導するための組成物及び方法 |
| TW202200199A (zh) | 2020-03-20 | 2022-01-01 | 美商百歐恩泰美國公司 | 冠狀病毒疫苗及使用方法 |
| WO2021194826A2 (en) | 2020-03-24 | 2021-09-30 | Icahn School Of Medicine At Mount Sinai | Recombinant sars-cov-2 spike protein and uses thereof |
| US20210299245A1 (en) | 2020-03-31 | 2021-09-30 | Sementis Limited | Attenuated poxvirus vector based vaccine for protection against covid-19 |
| US20240285751A1 (en) | 2020-04-01 | 2024-08-29 | Diosynvax Ltd | Coronavirus vaccines |
| US20230143228A1 (en) | 2020-04-21 | 2023-05-11 | Emory University | Coronavirus vaccines, compositions, and methods related thereto |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| US11130787B2 (en) * | 2020-06-11 | 2021-09-28 | MBF Therapeutics, Inc. | Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods |
| EP3928789A1 (en) * | 2020-06-24 | 2021-12-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
| JP2024505274A (ja) | 2021-02-02 | 2024-02-05 | ゲオバックス インコーポレイテッド | ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト |
-
2021
- 2021-02-12 EP EP21754084.8A patent/EP4103231A4/en active Pending
- 2021-02-12 KR KR1020227031509A patent/KR20220154114A/ko active Pending
- 2021-02-12 CN CN202180015836.7A patent/CN115529817A/zh active Pending
- 2021-02-12 CA CA3167052A patent/CA3167052A1/en active Pending
- 2021-02-12 WO PCT/US2021/018033 patent/WO2021163622A1/en not_active Ceased
- 2021-02-12 IL IL295482A patent/IL295482A/en unknown
- 2021-02-12 JP JP2022549163A patent/JP2023513611A/ja active Pending
- 2021-02-12 AU AU2021220991A patent/AU2021220991A1/en active Pending
- 2021-02-12 MX MX2022009962A patent/MX2022009962A/es unknown
- 2021-02-12 BR BR112022014884A patent/BR112022014884A2/pt unknown
- 2021-02-17 TW TW110105390A patent/TW202140794A/zh unknown
-
2022
- 2022-08-15 US US17/888,131 patent/US12577589B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220154114A (ko) | 2022-11-21 |
| IL295482A (en) | 2022-10-01 |
| CA3167052A1 (en) | 2021-08-19 |
| US12577589B2 (en) | 2026-03-17 |
| JP2023513611A (ja) | 2023-03-31 |
| US20220396810A1 (en) | 2022-12-15 |
| EP4103231A4 (en) | 2024-03-27 |
| WO2021163622A1 (en) | 2021-08-19 |
| BR112022014884A2 (pt) | 2022-10-11 |
| CN115529817A (zh) | 2022-12-27 |
| TW202140794A (zh) | 2021-11-01 |
| EP4103231A1 (en) | 2022-12-21 |
| AU2021220991A1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009962A (es) | Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2. | |
| MX2021003175A (es) | Vacuna contra el virus de la peste porcina africana. | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| MX2017002791A (es) | Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante. | |
| JP2016510989A5 (https=) | ||
| AU2018287159B2 (en) | Personalized vaccine | |
| CA2293692A1 (en) | Methods and reagents for vaccination which generate a cd8 t cell immune response | |
| MX2021015465A (es) | Vacuna para fiebre porcina africana. | |
| AU2009303788B2 (en) | Smallpox DNA vaccine and the antigens therein that elicit an immune response | |
| MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
| MX2017016273A (es) | Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante. | |
| WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| NZ598605A (en) | Vaccine against african horse sickness virus | |
| WO2006037038B1 (en) | Optimized vaccines to provide protection against ebola and other viruses | |
| JP2017503479A5 (https=) | ||
| WO2005046621A3 (en) | Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines | |
| RU2018122755A (ru) | Слитые белки fmdv-e2 и их применение | |
| WO2006073431A3 (en) | Avipox recombinants expressing foot and mouth disease virus genes | |
| MX390966B (es) | Vacunas contra el dengue | |
| RU2017132190A (ru) | Гибридные белки, содержащие модифицированные поверхностные гликопротеины альфавируса и опухолеассоциированный антиген, и способы, связанные с ними | |
| US20090053256A1 (en) | Poxvirus Methods And Compositions | |
| JP2021528367A5 (https=) | ||
| ZA202309287B (en) | Coronavirus vaccine comprising a mosaic protein | |
| WO2008127307A3 (en) | Induction of an immune response against dengue virus using prime-boost approach | |
| ZA202310905B (en) | Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same |